Abstract: A vehicle moving control apparatus executes a regeneration charge coasting control when a stored electricity amount is equal to or smaller than a first deceleration charge threshold while a deceleration condition for decelerating a vehicle is satisfied, and executes a normal coasting control when the stored electricity amount of is greater than the first deceleration charge threshold while the deceleration condition is satisfied.

Abstract: A control unit performs a lane departure suppression control when a host vehicle is about to depart from a traveling lane. The control unit determines whether a low impact collision has occurred. The control unit performs a secondary collision damage mitigation control when the low impact collision is determined to have occurred while the lane departure suppression control is being performed.

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: A computer-implemented method for controlling navigation includes generating an emotion data of a first user that illustrates emotion of the first user based on information received from a sensor. The method includes transmitting the emotion data of the first user to a controller configured to control a navigation of a second user. The first user and the second user are members of a same group. The method includes modifying the navigation of the second user according to the emotion data of the first user.

Abstract: This disclosure describes a vehicle system for identifying environmental objects within an operator's surroundings in a first window and removing object obstructions through a neural network in a second window to generate a rendered window, or scene, for display. As more windows are processed, the neural network may increase its understanding of the surroundings. The neural network may be a generative adversarial network (GAN) that may be trained to identify environmental objects by introducing noise data into those environmental objects. After receiving a first window from at least one camera on the vehicle, a rendered window may be created from a second window received from the at least one camera based on environmental objects identified within the first window through the GAN and removing object obstructions. The rendered window, without the object obstructions, and having superimposed environmental objects based on the GAN, may be displayed on an output device.

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: A computer-implemented method for controlling navigation includes generating an emotion data of a first user that illustrates emotion of the first user based on information received from a sensor. The method includes transmitting the emotion data of the first user to a controller configured to control a navigation of a second user. The first user and the second user are members of a same group. The method includes modifying the navigation of the second user according to the emotion data of the first user.

Abstract: This disclosure describes a vehicle system for identifying environmental objects within an operator's surroundings in a first window and removing object obstructions through a neural network in a second window to generate a rendered window, or scene, for display. As more windows are processed, the neural network may increase its understanding of the surroundings. The neural network may be a generative adversarial network (GAN) that may be trained to identify environmental objects by introducing noise data into those environmental objects. After receiving a first window from at least one camera on the vehicle, a rendered window may be created from a second window received from the at least one camera based on environmental objects identified within the first window through the GAN and removing object obstructions. The rendered window, without the object obstructions, and having superimposed environmental objects based on the GAN, may be displayed on an output device.

Abstract: A cosmetic material comprises (A) a hydrophobic powder; (B) a carboxylic acid modified silicone; (C) a basic compound; and (D) water. The (A) hydrophobic powder is generally dispersed in an aqueous phase of the cosmetic material. The cosmetic material can provide a refreshing sense of feel during use, and can form a cosmetic film with excellent water resistance on the skin.

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: A cosmetic material comprises (A) a hydrophobic powder; (B) a carboxylic acid modified silicone; (C) a basic compound; and (D) water. The (A) hydrophobic powder is generally dispersed in an aqueous phase of the cosmetic material. The cosmetic material can provide a refreshing sense of feel during use, and can form a cosmetic film with excellent water resistance on the skin.

Abstract: In many cases, the charged particle beam apparatus is used basically for observation at a magnification of 10,000 times or higher. It is thus difficult to recognize how the orientation of a sample seen with the naked eye corresponds to the origination of the sample appearing on an acquired image. This makes it difficult intuitively to grasp the tilt direction and other details of the sample. An object of this invention is to provide a charged particle beam apparatus allowing the orientation and the tilted state of the sample to be grasped intuitively.

Abstract: In many cases, the charged particle beam apparatus is used basically for observation at a magnification of 10,000 times or higher. It is thus difficult to recognize how the orientation of a sample seen with the naked eye corresponds to the origination of the sample appearing on an acquired image. This makes it difficult intuitively to grasp the tilt direction and other details of the sample. An object of this invention is to provide a charged particle beam apparatus allowing the orientation and the tilted state of the sample to be grasped intuitively.

Abstract: A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom, exhibits an excellent antitumor effect compared to cases where these are individually used.

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom, exhibits an excellent antitumor effect compared to cases where these are individually used.

Abstract: In order to suppress quick potential change on the surface of a process target when the shutter plate is opened and closed, when an ion beam IB from the ion source 10 is irradiated on a substrate 38 and the ion beam IB is neutralized by using neutralizing electrons e− generated by a microwave neutralizer 14, the shutter plate 62 shields the substrate 38 before and after the milling processing of the substrate 38, and the voltage of a power supply 34 is lowered when the shutter plate 62 is opened and closed so as to limit the amount of ion beam IB irradiation, thereby suppressing charge-up on the surface of the substrate 38.

Abstract: In order to suppress quick potential change on the surface of a process target when the shutter plate is opened and closed, when an ion beam IB from the ion source 10 is irradiated on a substrate 38 and the ion beam IB is neutralized by using neutralizing electrons e− generated by a microwave neutralizer 14, the shutter plate 62 shields the substrate 38 before and after the milling processing of the substrate 38, and the voltage of a power supply 34 is lowered when the shutter plate 62 is opened and closed so as to limit the amount of ion beam IB irradiation, thereby suppressing charge-up on the surface of the substrate 38.